BDR Pharma Unveils Prostate Cancer Treatment Drug in Oral Solution Form

India Pharma Outlook Team | Wednesday, 03 January 2024

 India Pharma Outlook Team

BDR Pharmaceuticals announced the launch of Enzalutamide oral solution for the treatment of prostate cancer, claiming to be the first company in the world to do so.

The company has introduced the Enzalutamide oral solution as BDENZA, in 32 mg/ml priced at Rs 27,000 for 150ml, BDR Pharmaceuticals said in a statement.This innovative formulation marks a significant step forward in providing an effective dosage form with lesser side effects in comparison to existing oral dosage forms of Enzalutamide, it added, as per economic times.

"Changing how we treat prostate cancer, BDENZA oral solution brings a mix of benefits to make things better for patients. It gives a strong 160 mg dose in just one small 5 ml serving, so there's less hassle associated with lots of pills," BDR Pharmaceuticals Director, Technical Formulation, Aravind Badiger, said.

Unlike fixed-dose tablets, doctors can tailor the dosage to each patient. This oral solution is easy on the stomach, so it does not cause nausea. Furthermore, it is sugar-free and tasty, making it simpler for patients, particularly those with taste alterations or dietary restrictions, to adhere with the treatment, he noted.

It is a more patient-friendly approach to prostate cancer treatment. According to Badiger, it can significantly improve patient compliance. According to the firm, introducing a novel drug delivery technology certified by the Drug Controller General of India (DCGI) will make it more affordable and accessible in India.

"BDENZA represents a paradigm shift in prostate cancer therapy. Its introduction aligns with our relentless pursuit to provide accessible and patient-centric healthcare solutions," BDR Group Director (Business Development), Raheel Shah, said.

© 2024 India Pharma Outlook. All Rights Reserved.